Supernus Pharmaceuticals Stock In The News
| SUPN Stock | USD 37.74 0.13 0.34% |
Our overall analysis of Supernus Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Supernus Pharmaceuticals. The specific impact of Supernus Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Supernus Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Supernus Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Supernus Pharmaceuticals Backtesting and Supernus Pharmaceuticals Hype Analysis. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.
Supernus |
Supernus Pharmaceuticals Today Top News and Investor Outlook
Supernus Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Supernus and other traded companies coverage with news coverage. We help investors stay connected with Supernus headlines for the 18th of January 2025 to make an informed investment decision based on correlating the impacts of news items on Supernus Stock performance. Please note that trading solely based on the Supernus Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Supernus Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Supernus earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Supernus Pharmaceuticals that are available to investors today. That information is available publicly through Supernus media outlets and privately through word of mouth or via Supernus internal channels. However, regardless of the origin, that massive amount of Supernus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Supernus Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Supernus Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Supernus Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Supernus Pharmaceuticals alpha.
Supernus Largest EPS Surprises
Earnings surprises can significantly impact Supernus Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2016-05-03 | 2016-03-31 | 0.09 | 0.08 | -0.01 | 11 | ||
2015-08-04 | 2015-06-30 | 0.02 | 0.03 | 0.01 | 50 | ||
2017-05-09 | 2017-03-31 | 0.22 | 0.19 | -0.03 | 13 | ||
2015-05-05 | 2015-03-31 | -0.01 | 0.02 | 0.03 | 300 | ||
2024-08-06 | 2024-06-30 | 0.31 | 0.36 | 0.05 | 16 | ||
2016-08-02 | 2016-06-30 | 0.13 | 0.18 | 0.05 | 38 |
Supernus Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Supernus Pharmaceuticals Stock. Current markets are strongly bullish. About 72% of major world exchanges and indexes are currently up. See today's market update for more information.
16th of January 2025
Burney Co. Purchases 71,331 Shares of Supernus Pharmaceuticals, Inc. - MarketBeat at news.google.com
7th of January 2025
Supernus Pharmaceuticals shareholders have earned a 9.4 percent CAGR over the last five ye... at finance.yahoo.com
23rd of December 2024
Acquisition by Jonathan Rubin of 750 shares of Supernus Pharmaceuticals subject to Rule 16... at MacroaxisInsider
16th of December 2024
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree in Canada at finance.yahoo.com
13th of December 2024
Newron and EA Pharma Announce License Agreement for Evenamide in Japan and Other Asian Ter... at businesswire.com
26th of November 2024
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference at gurufocus.com
21st of November 2024
Supernus Pharmaceuticals Reaches 80-Plus Relative Strength Rating Benchmark - Inkl at news.google.com
15th of November 2024
ARMISTICE CAPITAL, LLC Acquires Significant Stake in Rockwell Medical Inc at gurufocus.com
6th of November 2024
Supernus Pharmaceuticals, Inc. Q3 2024 Earnings Call Transcript at insidermonkey.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Supernus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Supernus Pharmaceuticals' short interest history, or implied volatility extrapolated from Supernus Pharmaceuticals options trading.
Check out Supernus Pharmaceuticals Backtesting and Supernus Pharmaceuticals Hype Analysis. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.06 | Revenue Per Share | Quarterly Revenue Growth 0.142 | Return On Assets |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.